科研平台

血浆蛋白质研究中心致力于血浆蛋白质基础及应用研究，开展血液蛋白质与疾病相关性及其疗效分子机制、血浆药效成分解析、血浆蛋白综合利用及血液制品与单采血浆法规标准和规范指南等研究。

本中心前身为中国医学科学院输血研究所血浆蛋白质研究室、血液生化与分子生物学研究中心，始建于1957年，已有超过60年的历史，2010年获批“四川省血浆蛋白质重点实验室”。自实验室建立以来，长期专注于血浆蛋白质研究，先后研究开发出中国第一支人血白蛋白、人免疫球蛋白、静脉注射免疫球蛋白、凝血因子Ⅷ浓缩制剂、凝血酶原复合物、α2-巨球蛋白和铁传递蛋白等近20种血浆蛋白产品及系列血栓与止血诊断产品，获多项省部级以上科研成果。

近年来先后承担国家“863”计划重点项目、国家公益性卫生行业科研重大专项、国家自然科学基金项目（海优、面上、青年等）、四川省科技攻关项目、四川省科技基础条件平台建设项目、四川省科技支撑计划项目及多项重大横向合作项目等。本着优势互补、合作共赢、共同发展的原则，分别与清华大学、北京协和医院、中国医学科学院血液学研究所和放射医学研究所等高校院所，以及成都蓉生、上海莱士、华润博雅、泰邦生物和华兰生物等业内头部机构合作共建，学科交叉，深入开展合作研究。

实验室现有全职科研人员14名，兼职研究员2名，其中高级专业技术职称人员11人，硕士以上学历人员13人。近年来先后在国内外核心学术期刊发表论文超过100篇，国家发明专利30余项，获四川省科技进步奖1项。

The Plasma Protein Research Center is dedicated to both fundamental and applied studies of plasma proteins, including investigations into the relationships between blood proteins and diseases, the molecular mechanisms underlying therapeutic effects, the characterization of plasma pharmacophore components, the comprehensive utilization of plasma proteins, and the development of regulatory standards and guidelines for blood products and plasma apheresis.

The center originated from the Plasma Protein Research Laboratory and the Center for Blood Biochemistry and Molecular Biology of the Chinese Academy of Medical Sciences, founded in 1957. It was designated the “Sichuan Provincial Key Laboratory of Plasma Proteins” in 2010.

Over the past six decades, the laboratory has developed nearly 20 plasma protein products, including China’s first human albumin, human immunoglobulin, intravenous immunoglobulin, coagulation factor VIII concentrate, prothrombin complex, α₂-macroglobulin, and transferrin, as well as diagnostic reagents for thrombosis and hemostasis—achievements recognized with multiple provincial and ministerial awards.

In recent years, the center has undertaken major national projects such as the “863” Program, national public health initiatives, multiple National Natural Science Foundation grants, and key provincial science and technology programs, along with major industry collaborations.

Following the principles of complementary strengths, win-win cooperation, and shared development, the center works closely with leading institutions including Tsinghua University, Peking Union Medical College Hospital, and institutes of the Chinese Academy of Medical Sciences, as well as companies such as Chengdu Rongsheng Pharmaceuticals, Shanghai RAAS, China Resources Boya-Bio, Taibang Biologic Group, and Hualan Bio.

The center includes 14 full-time and 2 adjunct researchers, with 11 senior professionals and 13 members holding master’s degrees or above. Recent accomplishments include over 100 publications, more than 30 national patents, 2 U.S. patents, and the Sichuan Provincial Science and Technology Progress Award.